182 related articles for article (PubMed ID: 10484986)
21. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase.
Ohnishi K; Ohno R; Tomonaga M; Kamada N; Onozawa K; Kuramoto A; Dohy H; Mizoguchi H; Miyawaki S; Tsubaki K
Blood; 1995 Aug; 86(3):906-16. PubMed ID: 7620184
[TBL] [Abstract][Full Text] [Related]
22. A long term follow-up of a randomized trial comparing interferon-alpha with busulfan for chronic myelogenous leukemia. The Kouseisho Leukemia Study Group.
Ohnishi K; Tomonaga M; Kamada N; Onozawa K; Kuramoto A; Dohy H; Mizoguchi H; Miyawaki S; Tsubaki K; Miura Y; Omine M; Kobayashi T; Naoe T; Ohshima T; Hirashima K; Ohtake S; Takahashi I; Morishima Y; Naito K; Asou N; Tanimoto M; Sakuma A; Ohno R
Leuk Res; 1998 Sep; 22(9):779-86. PubMed ID: 9716008
[TBL] [Abstract][Full Text] [Related]
23. A randomized study of intermediate as compared with high doses of interferon-alpha for chronic myeloid leukemia: no differences in cytogenetic responses.
Peñarrubia MJ; Odriozola J; González C; Massagué I; Miguel A; González San Miguel JD; Pérez Encinas M; Lavilla E; Giraldo MP; Casado LF; Ferrer S; Steegmann JL;
Ann Hematol; 2003 Dec; 82(12):750-8. PubMed ID: 14517691
[TBL] [Abstract][Full Text] [Related]
24. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
25. Effects of chemotherapy (busulfan-hydroxyurea) and interferon-alfa on bone marrow morphologic features in chronic myelogenous leukemia. Histochemical and morphometric study on sequential trephine biopsy specimens with special emphasis on dynamic features.
Thiele J; Kvasnicka HM; Schmitt-Graeff A; Bundschuh S; Biermann T; Roessler G; Wasmus M; Diehl V; Zankovich R; Schaefer HE
Am J Clin Pathol; 2000 Jul; 114(1):57-65. PubMed ID: 10884800
[TBL] [Abstract][Full Text] [Related]
26. Current aspects of drug therapy in Philadelphia-positive CML: correlation of tumor burden with survival.
Hehlmann R; Heimpel H
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():161-7. PubMed ID: 8951787
[TBL] [Abstract][Full Text] [Related]
27. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
Kantarjian HM; Talpaz M; O'Brien S; Smith TL; Giles FJ; Faderl S; Thomas DA; Garcia-Manero G; Issa JP; Andreeff M; Kornblau SM; Koller C; Beran M; Keating M; Rios MB; Shan J; Resta D; Capdeville R; Hayes K; Albitar M; Freireich EJ; Cortes JE
Clin Cancer Res; 2002 Jul; 8(7):2177-87. PubMed ID: 12114418
[TBL] [Abstract][Full Text] [Related]
28. [Treatment of chronic myeloid leukemia using alpha-interferon and hydroxyurea. Study of 30 cases].
Nese M; de Bellis R; Urtiarte R; Di Landro J
Sangre (Barc); 1994 Jun; 39(3):183-6. PubMed ID: 7940047
[TBL] [Abstract][Full Text] [Related]
29. Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia. Kouseisho Leukemia Study Group.
Ohnishi K; Minami S; Ueda T; Nishimura M; Tsubaki K; Takemoto Y; Takeshita A; Sao H; Kageyama S; Ueda R; Ohno R
Int J Hematol; 2000 Aug; 72(2):229-36. PubMed ID: 11039674
[TBL] [Abstract][Full Text] [Related]
30. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia.
Allan NC; Richards SM; Shepherd PC
Lancet; 1995 Jun; 345(8962):1392-7. PubMed ID: 7760609
[TBL] [Abstract][Full Text] [Related]
31. Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: the main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-alpha. Results of the CML89 trial of the Spanish Collaborative Group on interferon-alpha2a and CML.
Steegmann JL; Odriozola J; Rodriguez-Salvanés F; Giraldo P; García-Laraña J; Ferro MT; Benítez E; Pérez-Pons C; Giralt M; Escribano L; Lavilla E; Miguel A; Areal C; Pérez-Encinas M; Abad A; Maldonado J; Massagué I; Fernández-Rañada JM
Haematologica; 1999 Nov; 84(11):978-87. PubMed ID: 10553157
[TBL] [Abstract][Full Text] [Related]
32. Interferon-alpha and hydroxyurea in early chronic myeloid leukemia: a comparative analysis of the Italian and German chronic myeloid leukemia trials with interferon-alpha.
Hasford J; Baccarani M; Hehlmann R; Anseri H; Tura S; Zuffa E
Blood; 1996 Jun; 87(12):5384-91. PubMed ID: 8652857
[TBL] [Abstract][Full Text] [Related]
33. Relapse and cytogenetic evolution in myeloid neoplasms.
Ertz-Archambault N; Kelemen K
Panminerva Med; 2017 Dec; 59(4):308-319. PubMed ID: 29144072
[TBL] [Abstract][Full Text] [Related]
34. Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia.
Talpaz M; O'Brien S; Rose E; Gupta S; Shan J; Cortes J; Giles FJ; Faderl S; Kantarjian HM
Blood; 2001 Sep; 98(6):1708-13. PubMed ID: 11535501
[TBL] [Abstract][Full Text] [Related]
35. Gender aspects in chronic myeloid leukemia: long-term results from randomized studies.
Berger U; Maywald O; Pfirrmann M; Lahaye T; Hochhaus A; Reiter A; Hasford J; Heimpel H; Hossfeld DK; Kolb HJ; Löffler H; Pralle H; Queisser W; Hehlmann R;
Leukemia; 2005 Jun; 19(6):984-9. PubMed ID: 15830009
[TBL] [Abstract][Full Text] [Related]
36. Philadelphia chromosome-negative cells with trisomy 8 after busulfan and interferon treatment of Ph1-positive chronic myelogenous leukemia.
Izumi T; Imagawa S; Hatake K; Miura Y; Ariyama T; Inazawa J; Abe T
Int J Hematol; 1996 Jul; 64(1):73-7. PubMed ID: 8757971
[TBL] [Abstract][Full Text] [Related]
37. Progress with interferon in CML--results of the MRC UK CML III study.
Shepherd PC; Richards SM; Allan NC
Bone Marrow Transplant; 1996 May; 17 Suppl 3():S15-8. PubMed ID: 8769693
[TBL] [Abstract][Full Text] [Related]
38. Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors.
Wang W; Cortes JE; Lin P; Beaty MW; Ai D; Amin HM; McDonnell TJ; Ok CY; Kantarjian HM; Medeiros LJ; Hu S
Blood; 2015 Oct; 126(14):1699-706. PubMed ID: 26243778
[TBL] [Abstract][Full Text] [Related]
39. Interferon alpha in the treatment of chronic myelogenous leukemia.
Robak T
Arch Immunol Ther Exp (Warsz); 1998; 46(6):347-53. PubMed ID: 9883313
[TBL] [Abstract][Full Text] [Related]
40. [Recent progress in therapy for chronic myelogenous leukemia].
Urabe A
Gan To Kagaku Ryoho; 1997 Jul; 24(9):1066-73. PubMed ID: 9239158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
